Purpose: To report a case of hypoplastic trigeminal nerve associated with corneal epithelial disorders that were successfully treated with peptides derived from substance P and insulin-like growth factor-1 (IGF-1). Case Report: A 16-month-old boy was referred for treatment of a persistent corneal epithelial defect on his left eye. Magnetic resonance imaging revealed the apparent absence of the trigeminal nerve on the left side, and the patient was therefore diagnosed with neurotrophic keratopathy. Treatment with eye drops containing the tetrapeptides FGLM-NH2 and SSSR derived from the neuropeptide substance P and the growth factor IGF-1, respectively, resulted in resurfacing of the corneal epithelial defect. Discussion: The trigeminal nerve anomaly of the patient likely gave rise to neurotrophic keratopathy as a result of a deficiency of neural factors, emphasizing the importance of neural regulation in corneal epithelial homeostasis.
High serum lipoprotein(a) (Lp(a)) levels are associated with coronary artery disease. The serum Lp(a) levels of 130 patients with acute myocardial infarction (AMI) who underwent direct percutaneous coronary intervention were investigated. On the basis of Lp(a) level at 1 month after the onset of AMI, the patients were classified into 2 groups (high-Lp(a) (> or =30 mg/dl) and low-Lp(a) (< 30 mg/dl)) for evaluation of the clinical coronary stenosis progression (CCSP) rate. CCSP is defined as either target lesion revascularization (TLR) or new lesion revascularization (NLR). The CCSP rate was significantly higher in the high-Lp(a) group than in the low-Lp(a) group (65.8% vs 29.3%, p<0.01). In patients who had coronary stents in the acute phase (n=79), the CCSP and NLR rates were significantly higher in the high-Lp(a) group than in the low-Lp(a) group (45.0% vs 20.3%, p<0.05; 35.0% vs 6.8%, p<0.01), but there was no significant difference in TLR rate between the 2 groups (10.0% vs 13.6%, p=0.858). High serum Lp(a) level is a significant risk factor for CCSP, but does not influence restenosis after stenting.
Purpose: We have previously shown that the fibronectin-derived peptide PHSRN (Pro-His-Ser-Arg-Asn) promotes corneal epithelial wound healing in vivo. We have now examined the clinical efficacy of eye drops containing the PHSRN peptide for treatment of persistent epithelial defects (PEDs) of the cornea. Methods: Seven patients (5 men and 2 women; mean age ± SD, 78.3 ± 9.4 years) with PEDs were treated by administration of eye drops containing PHSRN. The duration of the PEDs before treatment was 7.4 ± 5.5 weeks. The eye drops were administered as 1 drop per eye 4 times a day. Epithelial defects were observed with a slit-lamp microscope and photographed during the treatment course. Results: Epithelial defects in 5 of the 7 affected eyes (71%) responded to PHSRN treatment as manifested by complete epithelial resurfacing within the 4-week period after treatment initiation. The mean ± SD time required for complete epithelial resurfacing in the 5 responding subjects was 15.8 ± 3.4 days. No adverse effects of treatment were observed in any of the subjects. Conclusions: Eye drops containing the fibronectin-derived PHSRN peptide are clinically efficacious for the treatment of PEDs.
1 December 2019 in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology